Clozapine Treatment During Pregnancy and the Postpartum Period: A Systematic Literature Review

Marieke M. Beex-Oosterhuis, PharmD; Arthur R. Van Gool, MD, PhD; Eibert R. Heerdink, PharmD, PhD; Charlotte van Kesteren, PharmD, PhD; Rob J. van Marum, MD, PhD

J Clin Psychiatry 2022;83(1):21r13952

ABSTRACT

Objective: The objective of this systematic review was to provide a critical appraisal of the evidence related to the safety of clozapine for schizophrenia during pregnancy and lactation.

Data Sources: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception through December 2020. Reference lists of included studies were hand-searched. The International Clinical Trials Registry Platform and ClinicalTrials.gov were searched for unpublished trials, and PROSPERO was searched for unpublished reviews. The current marketing authorization holder of the originator brands Clozaril and Leponex was also contacted for pharmacovigilance data.

Study Selection: Original reports published in English, German, French, or Dutch containing clinical and preclinical data were included if they provided data on maternal, fetal, and neonatal outcomes after clozapine exposure during pregnancy or lactation.

Data Extraction: Two reviewers independently extracted relevant data.

Results: A total of 860 records were identified, and the full texts of 117 articles were reviewed. Forty-two studies met the inclusion criteria. Data on perinatal clozapine exposure are of limited quality and quantity. Although clozapine demonstrates partial placental passage, data thus far do not support that clozapine is teratogenic; that it increases the risk of stillbirth, abortion, or fetal disorders; or that it increases the risk of delivery complications or premature birth. Information about clozapine exposure through breast milk is scarce, but based on its chemical properties, it is likely that clozapine enters the breast milk of nursing mothers taking clozapine.

Conclusions: When weighing the risks and benefits of clozapine continuation during pregnancy and lactation versus switching to another antipsychotic, one should include severity of illness and treatment history but also be aware of the limitations of the available safety data regarding perinatal clozapine use, including the fact that there are few studies.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (76)

Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55(suppl B):47–52. PubMed
Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173(2):166–173. PubMed CrossRef
Remington G, Lee J, Agid O, et al. Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf. 2016;15(9):1193–1203. PubMed CrossRef
Clozapine Product Manufacturers Group. Clozapine risk evaluation and mitigation strategy (REMS). Clozapine REMS. Accessed April 29, 2021. https://www.clozapinerems.com
Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001–2007: a population-based study of 585,615 deliveries. Arch Women Ment Health. 2013;16(2):149–157. PubMed CrossRef
Forrester T, Siskind D, Winckel K, et al. Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry. 2015;48(4-5):164–169. PubMed CrossRef
Gören JL, Rose AJ, Smith EG, et al. The business case for expanded clozapine utilization. Psychiatr Serv. 2016;67(11):1197–1205. PubMed CrossRef
Genees-en hulpmiddelen Informatie Project (GIP), Zorginstituut Nederland, The Netherlands. The drug information system of National Health Care Institute. GIPdatabank. Updated 2018. Accessed November 15, 2018. https://www.gipdatabank.nl/databank.asp
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Disease Primers. 2015. https://www.nature.com/articles/nrdp201567
Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry. 2016;173(3):263–270. PubMed CrossRef
Howard LML, Thornicroft G, Salmon M, et al. Predictors of parenting outcome in women with psychotic disorders discharged from mother and baby units. Acta Psychiatr Scand. 2004;110(5):347–355. PubMed CrossRef
Gilbert H. “About Helen”: antipsychotic medication use during pregnancy. A case study. Aust Nurs J. 2009;16(7):20.
Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918. PubMed
Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. PubMed CrossRef
Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Women Ment Health. 2017;20(1):1–9. PubMed CrossRef
Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
Westin AA, Brekke M, Molden E, et al. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther. 2018;103(3):477–484. PubMed CrossRef
Hatters Friedman S, Moller-Olsen C, Prakash C, et al. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int J Psychiatry Med. 2016;51(6):521–533. PubMed CrossRef
Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5):e94788. PubMed CrossRef
Bodén R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–721. PubMed CrossRef
Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279–288. PubMed CrossRef
Beex-Oosterhuis MM, Samb A, Heerdink ER, et al. Safety of clozapine use during pregnancy: analysis of international pharmacovigilance data. Pharmacoepidemiol Drug Saf. 2020;29(6):725–735. PubMed CrossRef
Montastruc F, Salvo F, Arnaud M, et al. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from vigibase. Drug Saf. 2016;39(7):689–696. PubMed CrossRef
Shao P, Ou J, Peng M, et al. Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. PLoS One. 2015;10(4):e0123373. PubMed CrossRef
Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192(5):333–337. PubMed CrossRef
Oltulu C, Karadag CH. The effect of intrauterine antipsychotic drug exposure on learning and memory in adult rats. Klin Psikofarmakol Bul. 2016;26(4):364–373. CrossRef
Donohoe DR, Weeks K, Aamodt EJ, et al. Antipsychotic drugs alter neuronal development including ALM neuroblast migration and PLM axonal outgrowth in Caenorhabditis elegans. Int J Dev Neurosci. 2008;26(3–4):371–380. PubMed CrossRef
Wang JH, Yang JZ, Wilson FAW, et al. Differently lasting effects of prenatal and postnatal chronic clozapine/haloperidol on activity and memory in mouse offspring. Pharmacol Biochem Behav. 2006;84(3):468–478. PubMed CrossRef
Nguyen T, Mordecai J, Watt F, et al. Obstetric and neonatal outcomes of clozapine exposure in pregnancy: a consecutive case series. Arch Women Ment Health. 2020;23(3):441–445. PubMed CrossRef
Imaz ML, Oriolo G, Torra M, et al. Clozapine use during pregnancy and lactation: a case-series report. Front Pharmacol. 2018;9:264. PubMed CrossRef
Molins C, Fortea A, Bioque M, et al. Clozapine and electroconvulsive therapy is an effective and safe treatment during pregnancy: a case report. J ECT. 2019;35(3):e30–e32. PubMed CrossRef
Narayanaswamy P, Shaji KS, Sumesh TP. Meningomyelocele on exposure to clozapine during prenatal period. Indian J Psychiatry. 2018;60(5):71.
Uygur ÖF, Uygur H. Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report. Psychiatry Clin Psychopharmacol. 2019;29(4):744–747. CrossRef
Hodge F, Amin P, Smith S. Case report: CTG abnormalities due to clozapine use. BJOG Int J Obstet Gynaecol. 2016;123:50.
Köse Çınar R. Olanzapine and clozapine use in a woman with schizophrenia during consecutive pregnancies: a case report. Drugs Ther Perspect. 2016;32(9):403–405. CrossRef
Sreeraj VS, Venkatasubramanian G. Safety of clozapine in a woman with triplet pregnancy: A case report. Asian J Psychiatr. 2016;22:67–68. PubMed CrossRef
Guyon L, Auffret M, Coussemacq M, et al. Alteration of the fetal heart rate pattern induced by the use of clozapine during pregnancy. Therapie. 2015;70(3):301–303. PubMed CrossRef
Coston A-L, Hoffmann P, Equy V, et al. Fetal heart rate variability and clozapine treatment. Gynécol Obstét Fertil. 2012;40(9):549–552. PubMed CrossRef
Moreno-Bruna MD, de Montgolfier I, Chabaud M, et al. Case report: neonatal delayed peristalsis after in-utero exposure to clozapine. Arch Pediatr. 2012;19(9):913–916. PubMed CrossRef
Novikova N, Chitnis M, Linder V, et al. Atypical antipsychotic (clozapine) self-poisoning in late pregnancy presenting with absent fetal heart rate variability without acidosis and delayed peristalsis in the newborn baby: a case report. Aust N Z J Obstet Gynaecol. 2009;49(4):442–444. PubMed CrossRef
Duran A, Ugur MM, Turan S, et al. Clozapine use in two women with schizophrenia during pregnancy. J Psychopharmacol. 2008;22(1):111–113. PubMed CrossRef
Kłys M, Rojek S, Rzepecka-Woźniak E. Neonatal death following clozapine self-poisoning in late pregnancy: an unusual case report. Forensic Sci Int. 2007;171(1):e5–e10. PubMed CrossRef
Mendhekar DN. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation. J Neuropsychiatry Clin Neurosci. 2007;19(2):196–197. PubMed CrossRef
Sethi S. Clozapine in pregnancy. Indian J Psychiatry. 2006;48(3):196–197. PubMed CrossRef
Doherty J, Bell PF, King DJ. Implications for anaesthesia in a patient established on clozapine treatment. Int J Obstet Anesth. 2006;15(1):59–62. PubMed CrossRef
Walch E, Blankenstein O, Bührer C. Conspicuous facies with microcephaly in intrauterine clozapine exposure. diagnosis: congenital hypothyroidism and trisomy 21, left middle-ear deafness. Monatsschr Kinderheilkd. 2005;153(11):1108–1110.
Gupta N, Grover S. Safety of clozapine in 2 successive pregnancies. Can J Psychiatry. 2004;49(12):863. PubMed CrossRef
Karakuła H, Szajer K, Spila B, et al. Clozapine and pregnancy: a case history. Pharmacopsychiatry. 2004;37(6):303–304. PubMed CrossRef
Mendhekar DN, Sharma JB, Srivastava PK, et al. Clozapine and pregnancy. J Clin Psychiatry. 2003;64(7):850. PubMed CrossRef
Nguyen HN, Lalonde P. Clozapine and pregnancy. Encephale. 2003;29(2):119–124. PubMed
Yogev Y, Ben-Haroush A, Kaplan B. Maternal clozapine treatment and decreased fetal heart rate variability. Int J Gynaecol Obstet. 2002;79(3):259–260. PubMed CrossRef
Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv. 1998;49(8):1081–1083. PubMed CrossRef
Tënyi TTM. Clozapine in the treatment of pregnant schizophrenic women. Psychiatr Danub. 1998;10(1):15–18.
Stoner SC, Sommi RWJ Jr, Marken PA, et al. Clozapine use in two full-term pregnancies. J Clin Psychiatry. 1997;58(8):364–365. PubMed CrossRef
Di Michele V, Ramenghi L, Sabatino G. Clozapine and lorazepam administration in pregnancy. Eur Psychiatry. 1996;11(4):214–219. PubMed CrossRef
Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother. 1995;6:197–208.
Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry. 1994;151(6):945. PubMed CrossRef
Waldman MDM, Safferman AZ. Pregnancy and clozapine. Am J Psychiatry. 1993;150(1):168–169. PubMed CrossRef
Tracy TS, Venkataramanan R, Glover DD, et al; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–639. PubMed CrossRef
Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425–428. PubMed CrossRef
Schoretsanitis G, Kane JM, de Leon J. Adding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature review. J Clin Psychopharmacol. 2020;40(3):308–310. PubMed CrossRef
Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–1220. PubMed CrossRef
Ke AB, Rostami-Hodjegan A, Zhao P, et al. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54(1):53–69. PubMed CrossRef
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 10th ed. Lippincott Williams & Wilkins; 2014.
Schaber G, Stevens I, Gaertner HJ, et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46(5):453–459. PubMed CrossRef
Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011.
Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001;33(2):161–235. PubMed CrossRef
Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990;18(1):20–36. PubMed CrossRef
O’Hara K, Wright IM, Schneider JJ, et al. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol. 2015;80(6):1281–1288. PubMed CrossRef
Jassen AK, Yang H, Miller GM, et al. Receptor regulation of gene expression of axon guidance molecules: implications for adaptation. Mol Pharmacol. 2006;70(1):71–77. PubMed CrossRef
Spencer GEG, Klumperman J, Syed NI. Neurotransmitters and neurodevelopment: role of dopamine in neurite outgrowth, target selection and specific synapse formation. Perspect Dev Neurobiol. 1998;5(4):451–467. PubMed
Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3(1):53–72. PubMed CrossRef
Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 2014;64(4):387–401. PubMed CrossRef
Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101–109. PubMed CrossRef
Webb RT, Pickles AR, King-Hele SA, et al. Parental mental illness and fatal birth defects in a national birth cohort. Psychol Med. 2008;38(10):1495–1503. PubMed CrossRef
Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 2014;5(2):100–109. PubMed CrossRef